Abstract: Disclosed are compositions including at least one 5.beta. steroid and an amorphous cyclodextrin. Also disclosed are methods for treating a condition such as obesity, diabetes syndrome, diabetes-associated hypercorticoidism, combinations thereof, and anemic disorders by administering to a mammal in need of such treatment a composition including an obesity-, diabetes-, or anemia antagonistic amount of at least one 5.beta. steroid and an amorphous cyclodextrin. Furthermore, disclosed are methods for treating a subject for a condition that responds to treatment with DHEA by administering to the subject at least one 5.beta. steroid and DHEA in an amount that minimizes the contribution of the DHEA to the production of testosterone and estradiol while maximizing an amount of .alpha.ET and .beta.ET circulating in the subject's blood from an initial dose administered to the subject.

Abstract: Various derivatives of barbituric acid and of diphenylhydantoin are described in which alkoxymethyl or benzyloxymethyl groups are attached to the nitrogen atoms of the rings. Therapeutic compositions containing these compounds and their use as anti-convulsant agents are described.

Abstract: Various derivatives of barbituric acid and of diphenylhydantoin are described in which alkoxymethyl or benzyloxymethyl groups are attached to the nitrogen atoms of the rings. Therapeutic compositions containing these compounds and their use as anti-convulsant agents are described.

Abstract: .beta.-Methoxyethoxymethyl esters of cephalosporins and penicillins are exemplified by such esters of hetacillin and heta-amoxicillin were synthesized and found to exhibit advantageous biological properties.

Abstract: It is disclosed that compounds of the formula: ##STR1## wherein Y represents (C.dbd.O).sub.m in which m has a value of 0 or 1; n has a value of 0 or 1; and X represents S, NH or O; provided that there is a COOH substituent at the 1, 2 or 3 position relative to the X group; and further provided that when X is NH and n is O, the COOH group cannot be at the 2 position; or a nontoxic, pharmaceutically acceptable salt thereof are capable of decreasing the ratio of the rates of bone resportion to bone deposition in a host animal, e.g., in the treatment of osteoporosis.

Abstract: It is disclosed that compounds of the formula: ##STR1## WHEREIN Y represents (C.dbd.O).sub.m in which m has a value of 0 or 1; n has a value of 0 or 1; and X represents S, NH or O; provided that there is a COOH substituent at the 1, 2 or 3 position relative to the X group; and further provided that when X is NH and n is 0, the COOH group cannot be at the 2 position; or a nontoxic, pharmaceutically acceptable salt thereof are capable of decreasing the ratio of the rates of bone resorption to bone deposition in a host animal, e.g., in the treatment of osteoporosis.

Abstract: It is disclosed that compounds of the formula: ##STR1## WHEREIN Y represents (C.dbd.O).sub.m in which m has a value of 0 or 1; n has a value of 0 or 1; and X represents S, NH or O; provided that there is a COOH substituent at the 1, 2 or 3 position relative to the X group; and further provided that when X is NH and n is O, the COOH group cannot be at the 2 position; and further provided that when n is 0, the carboxyl group is attached to the ring containing the X and Y ring members or a nontoxic, pharmaceutically acceptable salt thereof are capable of decreasing the ratio of the rates of bone resportion to bone deposition in a host animal, e.g., in the treatment of osteoporosis.

Abstract: N-mono(alkoxymethyl)phenobarbitals wherein the alkoxy group has 1 to 4 carbon atoms are disclosed. The compounds are prepared by reacting the dialkali metal salt of thiophenobarbital with chloromethyl alkyl ether followed by treating the resultant N,S-bis(alkoxymethyl)thiophenobarbital with an oxidizing agent. The compounds are useful as anti-convulsant agents.

Abstract: N-mono (alkoxymethyl)phenobarbitals wherein the alkoxy group has 1 to 4 carbon atoms are disclosed. The compounds are prepared by reacting the dialkali metal salt of thiophenobarbital with chloromethyl alkyl ether followed by treating the resultant N,S-bis(alkoxymethyl)thiophenobarbital with an oxidizing agent. The compounds are useful as anticonvulsant agents.

Abstract: Various derivatives of barbituric acid and of diphenylhydantoin are described in which alkoxymethyl or benzyloxymethyl groups are attached to the nitrogen atoms of the rings. Therapeutic compositions containing these compounds and their use as anticonvulsant agents are described.

Abstract: There is disclosed an improved process for the preparation of 1,3-bis(alkoxyalkyl)- and 1,3-bis(benzyloxyalkyl)-5,5-disubstituted barbituric acid derivatives, such as 1,3-bis(methoxymethyl)phenobarbital, by reacting e.g., phenobarbital, preferably, a multiple molar excess of dimethoxymethane and an at least equimolar amount of anhydrous stannic chloride based on the amount of phenobarbital.

Abstract: It is disclosed that 2-(4'-pyridyl)-1,3-dioxolane methiodide and 2-(1'-methyl-4'-piperidyl)-1,3-dioxolane hydroiodide are neuromuscular blocking agents or neuromuscular blocking agent antagonists, depending upon the amount of the drug administered.At doses of 10.sup.-.sup.6 to 10.sup.-.sup.4 gm./kg. of body weight, they antagonize or reverse the effects of neuromuscular blocking agents, such as d-tubocurarine and succinylcholine, produce post-drug repetitive activity (PDR), block post-tetanic potentiation (PTP), have no direct muscle effect and reverse the PTP suppression caused by d-tubocurarine and succinylcholine; and at doses of 10.sup.-.sup.3 to 10.sup.-.sup.2 gm./kg. of body weight they act as neuromuscular blocking agents.

Abstract: N-mono(alkoxymethyl)phenobarbitals wherein the alkoxy group has 1 to 4 carbon atoms are disclosed. The compounds are prepared by reacting the dialkali metal salt of thiophenobarbital with chloromethyl alkyl ether followed by treating the resultant N,S-bis(alkoxymethyl)thiophenobarbital with an oxidizing agent. The compounds are useful as anticonvulsant agents.

Abstract: 1,3-Bis(halomethyl)phenobarbitals are prepared by reacting phenobarbital with formaldehyde and a chlorine source or a bromine source at a temperature of -10.degree. to 200.degree.C in the presence of a Lewis acid catalyst, the formaldehyde and bromine or chlorine source being employed in at least approximately twice the molar amounts of phenobarbital. These compounds are useful anticonvulsant agents.

Abstract: 5-Pivaloyloxy-5-(1-phenylethyl) barbituric acid, a method of treating symptoms of pain in warm-blooded animals employing said compound and a therapeutic composition containing same are disclosed.